more_reports

Biotech Company Reports Promising Neurological Treatment in Clinical Study

  ()
Clinical-stage biotechnology company Coya Therapeutics Inc. (COYA:NASDAQ) announces positive interim results of a study for the treatment of patients with frontotemporal dementia (FTD). Read to see what catalysts one analyst said the stock can look forward to this year.
Tags: Biotechnology / Pharmaceuticals

Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Biotech Discovers Revolutionary Immunotherapy in Houston

Research Report
  ()
Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note.
Tags: Biotechnology / Pharmaceuticals

Analyst Reveals Undervalued Pharmaceutical Gem in Canada

Research Report
  ()
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential.
Tags: Biotechnology / Pharmaceuticals

Four-Year Data on New Drug for Early AD Positive

Research Report
  ()
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Rest of 2025 Rich With Catalysts for Immunotherapy Co.

Research Report
  ()
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

New Drug for Early AD Shown to be Efficacious, Safe

Research Report
  ()
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal

  ()
Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential.
Tags: Biotechnology / Pharmaceuticals

New Therapy for AATD Could be Best in Class

Research Report
  ()
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Share Price Appreciation of Biotech Due Over Next Six Months

Research Report
  ()
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe

  ()
Anavex Life Sciences Corp. (AVXL:NASDAQ) earned positive analyst coverage following new long-term data for blarcamesine in early Alzheimer's disease. Experts pointed to safety, durability, and potential approval pathways. Read more about what they said.
Tags: Biotechnology / Pharmaceuticals

Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.

  ()
OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Has Promising AI-Accelerated Pipeline

Research Report
  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy.
Tags: Biotechnology / Pharmaceuticals

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results

  ()
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) is gaining attention with strong Phase 3 results for its lead CNS candidate, brilaroxazine. Here's what analysts are seeing in its long-term potential.
Tags: Biotechnology / Pharmaceuticals

Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon

Research Report
  ()
Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Regenerative Medicine Firm OK'd To Advance Trial in T1D

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication.
Tags: Medical DevicesRegenerative Medicine

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Cell Pouch Co. Peer Aborts Program Using Like Device

Research Report
  ()
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report.
Tags: Medical DevicesRegenerative Medicine

New Jersey Pharma Co. Shares Positive Pediatric Study

Research Report
  ()
Aquestive Therapeutics Inc. (AQST:NASDAQ) recently reported that it completed New Drug Application (NDA) submission for Anaphylm and positive pediatric study data for the non-device-based epinephrine product candidate, noted an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth

  ()
BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story.
Tags: Medical DevicesTechnologySpecial Situations

GMP Production of Exosomes Slated for Later This Year

Research Report
  ()
This is a next big step for the biotech in moving its investigational exosome therapy for chronic inflammation into the clinic, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases

  ()
Clinical-stage biotechnology company Coya Therapeutics Inc.'s (COYA:NASDAQ) regulatory T cell-derived exosome (Treg exosome) program is set to enter Good Manufacturing Production (GMP) late this year, paving the way for an initial clinical study. Find out why one analyst calls the company's work a "potential breakthrough."
Tags: Biotechnology / Pharmaceuticals